4//SEC Filing
Talecris Biotherapeutics Holdings Corp. 4
Accession 0001225208-11-015862
CIK 0001405197operating
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 2:14 PM ET
Size
8.1 KB
Accession
0001225208-11-015862
Insider Transaction Report
Form 4
LYNCH THOMAS J
Sr. VP, Corp. Compliance
Transactions
- Disposition to Issuer
Options (right to buy)
2011-06-01−5,224→ 0 totalExercise: $19.00Exp: 2019-09-30→ Common Stock (5,224 underlying) - Disposition to Issuer
Common Stock
2011-06-01−3,655→ 0 total
Footnotes (2)
- [F1]Disposed of pursuant to the merger agreement between Issuer, Stream Merger Sub, Inc., Grifols, S.A., and Grifols, Inc. in exchange for $19.00 in cash and 0.6485 non-voting (Class B) ordinary shares of Grifols, S.A. (the Grifols B shares) (in the form of American Depository Shares (the Grifols ADS); with each Grifols ADS representing one-half of one Grifols B share) per Issuer share, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.
- [F2]This option, which provided for vesting in three equal annual installments beginning April 1, 2011, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of Issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6485 Grifols ADSs per Issuer share deemed issued, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.
Documents
Issuer
Talecris Biotherapeutics Holdings Corp.
CIK 0001405197
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001405197
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 2:14 PM ET
- Size
- 8.1 KB